Skip to content

Personalized Live-remote Exercise Training for Cancer Survivors

Demonstrating the (Cost-)Effectiveness of a Personalized Live-remote Exercise Intervention for Cancer Survivors Using a Super Umbrella Randomized Controlled Trial: the LION RCT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06270628
Acronym
LION
Enrollment
350
Registered
2024-02-21
Start date
2024-02-14
Completion date
2027-10-31
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

cancer survivors, exercise, live remote, personalized exercise training

Brief summary

Background Many people with cancer face ongoing problems from their disease and treatments, like fatigue, reduced physical fitness, feeling anxious or down, and neuropathy. While exercise might help with these problems, most studies did not focus on tailoring exercise to address these specific complaints. Exercise programs under supervision (like with a trainer) seem to work better, but barriers for following such sessions are travel distance and time. Therefore, following an exercise program at home with a trainer guiding via video (live-remote) might be a good solution. But, it is unclear how effective this remote exercise program is for cancer patients. Goal of the study: The main goal of this study is to assess the effectiveness of a personalized, live-remote exercise intervention for cancer survivors on quality of life and the patients' main complaint. The four complaints tackled in this study are: 1) fatigue, 2) reduced physical functioning, 3) anxiety and/or depressive symptoms, and 4) neuropathy. Design of the study In the LION study, 350 cancer patients will be randomly divided into the exercise group or control group. These patients all have at least one of these complaints: 1) fatigue, 2) reduced physical functioning, 3) anxiety and/or depressive symptoms, and/or 4) neuropathy. Patients cannot participate in the study if they are already very active. The exercise group will start a 12-week exercise program right away, and the other group will wait for 12 weeks before starting. The exercise program consists of three sessions per week. Two sessions per week include aerobic training and strength training. These sessions will be followed by all patients; and aim to improve fitness and strength. The third session specifically aims at improvement of the main complaint, for example fatigue. Participants will get an app and a fitness tracker to help them stay on track with their exercises. Furthermore, patients get information on the effects of exercise for cancer patients and why exercise is important for specific complaints. Measurements The main outcomes of this study are quality of life and the main side-effect of the patient. Other measurements include all kind of patient reported outcomes (like sleep problems and pain), physical fitness, muscle strength, balance, anthropometrics, and (inflammatory) markers in blood. Conclusion: This study investigates if personalized exercises done at home, with video guidance, can make cancer survivors feel better and manage their side effects more effectively.

Detailed description

SUMMARY Rationale: Many cancer patients suffer from long-term treatment-related side-effects like fatigue, low physical functioning, anxiety and/or depressive symptoms, and chemotherapy-induced peripheral neuropathy (CIPN). There is convincing evidence on the beneficial effects of general exercise interventions on these side-effects. However, studies to date generally fail to specifically screen for (long-term) side-effects at baseline and tailor the intervention to these specific side-effects, although larger exercise effects are observed in patients with a high symptom burden at baseline (e.g., with higher levels of fatigue). Larger effects of exercise are also observed for supervised exercise compared to unsupervised exercise. However, two of the most common barriers for attending and complying with supervised exercise are travel distance and time. An effective approach might be to provide live-remote supervision for exercise interventions. In this scenario, patients can receive guidance from a certified exercise specialist through a video-conferencing platform such as Zoom, while performing exercises within the comfort of their own homes. Currently, the effectiveness of live-remote exercise in cancer patients has not been established. Objective: The primary objective of the LION RCT is to assess the (cost-)effectiveness of a personalized, live-remote exercise intervention for cancer survivors on Health-Related Quality of Life (HRQOL) and the participants' main, self-reported side-effect. The four side-effects targeted in this study are: 1) fatigue, 2) perceived low physical functioning in daily life, 3) anxiety and/or depressive symptoms, and 4) CIPN. Study design: The LION RCT is a randomized controlled trial with two study arms: an exercise group (12 weeks) and a wait list control group. A super umbrella design will be used, allowing us to evaluate four exercise modalities (i.e., exercise modules based on participants' main side-effect) in a wide variety of cancer survivors. Study population: For this study, 350 adult cancer survivors treated with systemic chemotherapy (≥ 12 weeks to 1 year after completion of primary treatment of invasive cancer with curative intent) will be recruited independent of their primary cancer diagnosis. Participants will have reported at least one of the following side-effects: fatigue, low physical functioning in daily life, anxiety and/or depressive symptoms, CIPN. Additionally, participants need to be relatively physically inactive, i.e., perform ≤210 minutes/week of moderate-to-vigorous leisure and sports activities. Intervention: The intervention consists of three live-remote exercise sessions per week. Participants randomized to the exercise group receive the intervention after the baseline visit and the wait list control participants after the 12-week follow-up visit. A modular approach will be used to tailor the intervention to each participant's specific main side-effect. Each participant will receive the same base module (twice a week) to address HRQOL and in addition one out of four specific modules (once a week) addressing their individual main side-effect. In addition to the live-remote training, participants will be provided with the LION app and an activity tracker (Fitbit) at the start of the intervention to support exercise beyond the supervised program, during holidays and after the end of the intervention. In addition to exercise, the intervention also has an educational component including information about general effects of exercise for cancer patients and why exercise is important for specific side-effects. We consider the provision of such education as an integral part of adequate exercise programming. After the intervention period of 12 weeks, we follow the patients until 36 weeks. In this follow-up period, also two sub studies take place: 1. Sensor-based guidance sub study (only control patients from Cologne) 2. Live-remote physical fitness and function testing (in all control patients; all sites)

Interventions

BEHAVIORALExercise group

Live-remote exercise sessions, personalized to the patients main side-effect

Sponsors

UMC Utrecht
Lead SponsorOTHER
German Cancer Research Center
CollaboratorOTHER
German Sport University, Cologne
CollaboratorOTHER
Cabrini Health (CAB), Malvern, Australia
CollaboratorUNKNOWN
Karolinska Institute (KI), Stockholm, Sweden
CollaboratorUNKNOWN
The Netherlands Cancer Institute
CollaboratorOTHER
Heidelberg University Clinic and National Center for Tumor Diseases, Heidelberg, Germany
CollaboratorUNKNOWN
Fundacion Onkologikao (ONK), San Sebastian, Spain
CollaboratorUNKNOWN
Associação de Investigação e Cuidados de Suporte em Oncologia (AISCO), Nova de Gaia, Portugal
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

RCT with two study arms: exercise group and wait list control group

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

To be eligible to participate in this study, a subject must be: * 18 years of age or older * Diagnosed with any type of invasive cancer and have received systemic chemotherapy as part of their primary cancer treatment * Within the timeframe of 12 weeks to 1 year after the completion of their primary cancer treatment with curative intent. Primary treatment, in this context, includes surgery, radiotherapy, and/or chemotherapy. For patients undergoing endocrine, targeted, or immunotherapy, their treatment must not be scheduled to be discontinued within the next 6 months. * No evidence of distant metastatic disease (i.e., no diagnosis of metastatic disease in the regular clinical trajectory) * ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2 * Presence of at least one of the following side-effects: fatigue (measured using EORTC QLQ-C30 fatigue symptom scale, score \>39), perceived low physical functioning in daily life (measured using EORTC QLQ-C30 physical functioning scale, score \<83), anxiety or depressive symptoms (measured using PHQ-ADS \> 20), and/or CIPN (measured using 2 PRO-CTCAE items, score \>0) for patients who received neurotoxic chemotherapy. Cut-off values are based on established thresholds.19-21 * Access to good quality and stable internet connection to access the live-remote training sessions. * Able and willing to perform the exercise program and wear the activity tracker at least one week after T0 and before T2, T4, and T5 measurements and during training and online assessment sessions. * Able to read, speak and understand the main country language.

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study: * Too physically active (i.e., \>210 minutes/week of self-reported moderate-to-vigorous or leisure and sports activities; this threshold has also been used in other exercise RCTs, such as PREFERABLE-EFFECT22, and fits activity levels of all participating countries) or participation in an exercise program comparable to the LION exercise program. * Following, or planned to follow, a structured psychological intervention during the intervention period, i.e., cognitive behavioral therapy, or unstable on psychotropic medication * Participated in the intervention group of an exercise study during cancer treatment * Inability to complete the testing or training sessions or any other contraindications for exercise as determined by the treating physician, including: * Severe neurologic or cardiac impairment according to ACSM criteria * Uncontrolled severe respiratory insufficiency or dependence on oxygen suppletion in rest or during exercise * Uncontrolled pain All these

Design outcomes

Primary

MeasureTime frameDescription
Health-Related Quality of LifeWeek 0 - Week 12Measured with the summary scale of the EORTC QLQ-C30; min 0- max 100 points; higher scores mean better quality of life
A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baselineWeek 0 - Week 12Side-effect 1: Fatigue measured with EORTC QLQ-FA12. According to a standardization procedure the symptom score of all patients will be combined into one symptom score..

Secondary

MeasureTime frameDescription
Health-related quality of lifeWeek 0 - Week 36Domains of the EORTC QLQ-C30 (except summary score)
FatigueWeek 0 - Week 36Cancer-Related fatigue measured with the EORTC-FA12
Anxiety and DepressionWeek 0 - Week 36Anxiety and depressive symptoms measured with the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
CIPN_1Week 0 - Week 36Chemotherapy-induced peripheral neuropathy measured with EORTC QLQ-CIPN-20
CIPN_2Week 0 - Week 362 items of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Sleep0-36 weeksPittsburgh Sleep Quality Index (PSQI)
Pain prevalence and typeWeek 0 - Week 36EORTC QLQ-SURV100
Cognitive problemsWeek 0 - Week 36Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)
Work limitationsWeek 0 - Week 36Work Limitations Questionnaire (WLQ)
Body imageWeek 0 - Week 36Body Image Scale (BIS)
Fear of cancer recurrence0-36 weeksEORTC QLQ-surv100
Habitual physical activityWeek 0 - Week 36Modified Godin-Shephard Leisure-Time Physical Activity Questionnaire
Aerobic capacity on bikeWeek 0 - Week 24Steep ramp test
Aerobic capacity on stepWeek 0 - Week 24Chester step test
Handgrip strengthWeek 0 - Week 24Handgrip test
Upper body muscle strengthWeek 0 - Week 24Chest press
Lower body muscle strength0-24 weeksLeg press
Sit to stand testWeek 0 - Week 2430 sec sit to stand test- function test
Physical functionWeek 0 - Week 24Time Up and Go (TUG) test
BalanceWeek 0 - Week 24Single leg stance test with open and closed eyes
Physical activity0-36 weeksMeasured with an activity tracker (Fitbit)
Blood pressure0-24 weeksMeasured twice with blood pressure device
Resting heart rateWeek 0 - Week 24Measured with blood pressure device
WeightWeek 0 - Week 24Weight. in KG
HeightWeek 0 - Week 24Height in cm
Waist circumferenceWeek 0 - Week 24Waist circumference in cm
Hip circumferenceWeek 0 - Week 24Hip circumference in cm
Body compositionWeek 0 - Week 24Fat mass and fat free mass with bio-impedance - three centers
Inflammatory state0-12 weeksThe specific inflammatory markers (e.g., cytokines, interleukins) will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms; we will for example use the Olink PEA platform (Oncology and Inflammation Array)
Growth factors0-12 weeksThe specific growth factors will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms ; we will for example use the Olink PEA platform (Oncology and Inflammation Array)
CRPWeek 0 - Week 12Blood cell count
Hemoglobin0-12 weeksBlood cell count
Leucocyte counts0-12 weeksBlood cell count
Quality-adjusted life yearsWeek 0 - Week 36EuroQol-5D-5L
Health-care, patient and family costsWeek 0 - Week 36Modified Medical Consumption Questionnaire (iMCQ)
Productivity lossesWeek 0 - Week 36Modified Productivity Cost Questionnaire (iPCQ)
Exercise-related (serious) adverse eventsWeek 0 - Week 36Via CASTOR app before and after each session; asked at and at the study visits.

Countries

Netherlands

Contacts

CONTACTEvelyn Monninkhof, PhD
e.monninkhof@umcutrecht.nl+3161118187
CONTACTAnne May, PhD
a.m.may@umcutrecht.nl+3161118187

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 12, 2026